Reach Neuro is a biotechnology company developing brain-computer interface (BCI) technologies for the treatment of neurological conditions, with a primary focus on stroke rehabilitation and motor recovery. Founded in 2021 and headquartered in Pittsburgh, Pennsylvania, Reach Neuro develops implantable neural interfaces that enable patients to regain motor function after stroke[1].
The company's flagship product, the ReNeuro system, is a minimally invasive brain-computer interface designed to decode neural signals and stimulate targeted brain regions to promote neuroplasticity and functional recovery in stroke patients[2].
The Reach Neuro ReNeuro system consists of:
| Component | Description |
|---|---|
| Neural Array | 64-channel microelectrode array |
| Implant | Miniaturized wireless transmitter |
| External Unit | Signal processing and control |
| Stimulation | Integrated electrical stimulation |
| Software | Machine learning decoder |
The ReNeuro system works through several mechanisms:
Reach Neuro's primary indication is chronic stroke motor recovery:
| Study | Phase | Participants | Status |
|---|---|---|---|
| REBUILD | Feasibility | 10 patients | Completed |
| RECOVER | Pilot | 30 patients | Recruiting |
| RESTORE | Pivotal | 150 patients | Planned |
Primary endpoints:
Reach Neuro competes in the neurorehabilitation BCI space:
| Company | Product | Technology | Stage |
|---|---|---|---|
| MindMaze | MindMotion | VR+BCI | Commercial |
| Motus | HandTutor | Robotic+BCI | Commercial |
| Reach Neuro | ReNeuro | Implantable | Clinical |
| Synchron | Stentrode | Vascular BCI | Clinical |
| Feature | Reach Neuro Advantage |
|---|---|
| Bidirectional | Recording + stimulation |
| Spatial resolution | High-density arrays |
| Plasticity induction | Coordinated stimulation |
| Chronic use | Long-term implantation |
| Program | Indication | Stage | Timeline |
|---|---|---|---|
| ReNeuro | Chronic stroke | IDE approved | Ongoing trials |
| ReNeuro-PD | Parkinson's disease | Preclinical | 2026 |
| ReNeuro-TBI | Traumatic brain injury | Discovery | 2027 |